Phase III trial shows vosaroxin improves overall survival in acute myeloid leukaemia
Minimal residual disease (MRD) as a prognostic factor for acute myeloid leukemia (AML)
Gerrit Jan Schuurhuis
How is the landscape of Hodgkin lymphoma therapy changing?
Should we be focusing on treating MM?
The use of immunophenotyping to assess minimal residual disease (MRD) in multiple myeloma